{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:07:42Z","timestamp":1784272062939,"version":"3.55.0"},"reference-count":38,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"abstract":"<jats:p>Clinical trials are crucial for medical progress, but patient recruitment remains their biggest challenge. The decision to participate stems from a combination of altruistic motivations and the desire to obtain better treatment. The physician plays a key role through their empathy, trustworthiness, and ability to explain the benefits and risks. Problems such as complex protocols, frequent visits, lack of knowledge about the trials, and distrust of pharmaceutical companies significantly hinder recruitment. Patients with chronic pain often hesitate despite severe symptoms, which further complicates the process. It is also important to provide access to study results in the form of understandable plain language summaries, which strengthen patient engagement. Designing \u201cpatient-centred\u201d studies can significantly improve their accessibility and effectiveness.<\/jats:p>","DOI":"10.5114\/reum\/218877","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:58:07Z","timestamp":1784271487000},"page":"332-337","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trials in rheumatology: patient motivations and concerns as key determinants of recruitment"],"prefix":"10.5114","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8070-1530","authenticated-orcid":true,"given":"Marta","family":"Jeka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref-1935356","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e300"},{"key":"ref-1935357","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes278"},{"key":"ref-1935358","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/195012"},{"key":"ref-1935359","doi-asserted-by":"publisher","DOI":"10.5603\/RF.a2023.0014"},{"key":"ref-1935360","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex278"},{"key":"ref-1935361","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.80710"},{"key":"ref-1935362","unstructured":"Obarska I. Nier\u00f3wno\u015bci w dost\u0119pie do leczenia biologicznego w chorobach autoimmunizacyjnych w Europie. Refundacja apteczna szans\u0105 na popraw\u0119 efektywno\u015bci leczenia w Polsce. Polski Zwi\u0105zek Pracodawc\u00f3w Przemys\u0142u Farmaceutycznego, Warszawa 2022. Available at: https:\/\/ptr.info.pl\/raporty\/raport-nierownosci-w-dostepie-do-leczenia-biologicznego-w-chorobach-autoimmunizacyjnych-w-europie-refundacja-apteczna-szansa-na-poprawe-efektywnosci-leczenia-w-polsce\/ (Access: 09.12.2025)."},{"key":"ref-1935363","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.1999.tb01217.x"},{"key":"ref-1935364","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2021-100540"},{"key":"ref-1935365","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2022-002044"},{"key":"ref-1935366","doi-asserted-by":"publisher","DOI":"10.5603\/RF.a2023.0017"},{"key":"ref-1935367","unstructured":"Clinical Trials: A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM). Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT01710358#study-plan (Access: 09.12.2025)."},{"key":"ref-1935368","unstructured":"Clinical Trials: A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05489224 (Access: 09.12.2025)."},{"key":"ref-1935369","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01453-8"},{"key":"ref-1935370","doi-asserted-by":"publisher","DOI":"10.1136\/jme.2009"},{"key":"ref-1935371","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5617575"},{"key":"ref-1935372","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1105-3"},{"key":"ref-1935373","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e403"},{"key":"ref-1935374","doi-asserted-by":"publisher","DOI":"10.1177\/20542704231166621"},{"key":"ref-1935375","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023"},{"key":"ref-1935376","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2022.09.001"},{"key":"ref-1935377","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05393-4"},{"key":"ref-1935378","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05599-0"},{"key":"ref-1935379","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05417-5"},{"key":"ref-1935380","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70035"},{"key":"ref-1935381","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.07.010"},{"key":"ref-1935382","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2023.107861"},{"key":"ref-1935383","doi-asserted-by":"publisher","DOI":"10.5070\/D329361423"},{"key":"ref-1935384","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036056"},{"key":"ref-1935385","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.07.008"},{"key":"ref-1935386","doi-asserted-by":"publisher","DOI":"10.2196\/29691"},{"key":"ref-1935387","unstructured":"https:\/\/www.wma.net\/policies-post\/wma-declaration-of- helsinki\/ [date of entry: 06\/JAN\/2026]."},{"key":"ref-1935388","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/206009"},{"key":"ref-1935389","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"ref-1935390","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp058136"},{"key":"ref-1935391","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14140"},{"key":"ref-1935392","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae016"},{"key":"ref-1935393","doi-asserted-by":"crossref","unstructured":"Eastell R, Jeka S, Lustberg M, et al. Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health. Ther Adv Musculoskelet Dis 2025; 17: 1759720X251335147, DOI: 10.1177\/ 1759720X251335147.","DOI":"10.1177\/1759720X251335147"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-218877-142481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-218877-142481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:58:27Z","timestamp":1784271507000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Clinical-trials-in-rheumatology-patient-motivations-and-concerns-as-key-determinants,218877,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["218877"],"URL":"https:\/\/doi.org\/10.5114\/reum\/218877","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}